Hemophilia Treatment Market size to exceed $16bn by 2028

Hemophilia Treatment Market size is set to exceed USD 16 billion by 2028, according to a new research report by Global Market Insights Inc.
 

Surging investments in R&D activities related to hemophilia treatment have contributed to the expansion of a robust product pipeline, further boosting the market size. The studies emphasizing on exploring the possibility of treating this ailment with gene therapy have evolved in recent years. Increasing interest in the development of novel treatment options through partnerships between key industry players as well as regulatory agencies is further anticipated to fuel the market growth.
 

The major market players are collaborating for augmenting the development of effective drugs to help the management of hemophilia among pediatric and adult patients. For instance, Bayer Healthcare collaborated with Children's Hospital of Philadelphia for the discovery of small molecules (SMOLs) to develop a first-in-class treatment for hemophilia A & B. Such wide-ranging efforts have enabled the development of novel therapies that have helped the patients efficiently. The extensive research activities pertaining to the identification of novel treatment and adopting stringent clinical trial designs to complement the strong R&D initiatives are expected to strengthen the hemophilia treatment drugs pipeline during the estimation timeframe.
 

Growing adoption of prophylaxis treatment is set to boost the market statistics

The rising adoption of prophylaxis treatment is projected to fuel the hemophilia treatment market share. Patients suffering from severe hemophilia are suggested to use the prophylaxis treatment solution to prevent bleeding. Prophylactic therapy is recommended for both pediatric and adult patients suffering from severe hemophilia B in order to prevent bleeds before they occur. The several benefits associated with these treatment options reduce the complications related to recurrent bleeding comprising intracranial hemorrhage and joint damage in patients with severe hemophilia A & B. According to the research studies, as compared to on-demand therapy, prophylaxis treatment significantly lessens bleeding in adult patients with hemophilia A. Owing to continuous advancements, this treatment has attained significance as an alternative therapy to maintain clotting factors above a baseline level. Thus, the above-mentioned factors are set to proliferate the adoption of prophylaxis treatment, thereby accelerating the hemophilia treatment industry landscape.
 

Growing incidence of hemophilia B is expected to foster the demand for hemophilia treatment, thereby driving the market trends

Based on disease, the hemophilia treatment market is segmented as hemophilia A and hemophilia B. Hemophilia B segment is anticipated to register 3.5% CAGR through 2028. This considerable segment growth is owing to surging R&D initiatives especially on identifying therapeutic agents for the treatment of hemophilia B, supportive initiatives for the early screening of hemophilia B, and rising severity of the disease with the genetic evolution among others. The patients suffering from hemophilia B need precise treatment to achieve adequate blood clotting and to avoid difficulties related to the condition, thereby boosting segmental revenue positively.
 

As per the article published in 2020, hemophilia B constitutes around 20% of hemophilia cases, and around 50% of these conditions have factor IX levels of more than 1%. Thus, the growing incidence of hemophilia B coupled with favourable initiatives is expected to augment the market revenue significantly.
 

Rising preference for plasma-derived factor concentrates are expected to propel the market growth

Based on product, the hemophilia treatment market is segmented as recombinant factor concentrates, plasma-derived factor concentrates, extended half-life products, and others. The plasma-derived factor concentrates segment exceeded USD 1,222 million in 2021 and is projected to progress with significant growth in the coming years. This significant growth is owing to a rising preference for plasma-derived factor concentrates in hemophilia treatment across the globe. These products are widely used as a significant therapeutic option for pediatric and adult patients. The advent of novel manufacturing techniques has reduced the risk of pathogen transmission related to the administration of plasma-derived factor concentrates. These advancements are expected to fuel the demand for plasma-derived products in the coming years.
 

Browse key industry insights spread across 350 pages with 791 market data tables & 24 figures & charts from the report, “Hemophilia Treatment Market Analysis By Disease (Hemophilia A {Severe, Moderate, Mild}, Hemophilia B {Severe, Moderate, Mild}), By Product (Recombinant Factor Concentrates {Factor VIII, Factor IX}, Plasma-derived Factor Concentrates {Factor VIII, Factor IX}, Extended Half-life Products {Factor VIII, Factor IX}), By Patient (Pediatric {0 to 4, 5 to 13, 14 to18}, Adult {19 to 44, 45+}), By Treatment (Prophylaxis, On Demand), By Therapy (Factor Replacement Therapy, Non-factor Replacement Therapy), By Drug Class (Vasopressin, Coagulation Factors), By Route of Administration (Injectable, Nasal Spray), By End-use (Hospitals, Clinics, Hemophilia Treatment Centers), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2022 – 2028” in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/hemophilia-treatment-market
 

High number of advantages pertaining to the use of hemophilia treatment procedures in pediatric patients is expected to fuel the market statistics

Based on patient, the hemophilia treatment market is segmented as pediatric and adult. The pediatric segment is anticipated to expand at 5.1% CAGR to reach around USD 6,081 million by 2028. This notable segment growth is due to the growing adoption of hemophilia disease treatment among pediatric patients. Children with hemophilia disorder bleed more with surgeries, bruise easily, have frequent nosebleeds, etc. According to a recent research article, in developed countries, most pediatric patients with hemophilia are treated with recombinant FVIII/FIX, primarily due to their higher safety.
 

Further, the National Hemophilia Foundation (NHF) is actively working to find improved treatments for bleeding disorders comprising hemophilia through education, advocacy, and research for pediatric patients. Recurrent hemarthrosis is a common complication associated with hemophilia among pediatric patients that increases the risk of developing severe arthropathy and joint contractures later in life. As a result, the complications associated with hemophilia in pediatric patients are expected to surge the demand for precise and advanced hemophilia treatment, thereby fueling the market revenue positively.
 

Growing adoption of on-demand hemophilia treatment is anticipated to intensify the business landscape

Based on treatment, the hemophilia treatment market is segmented as prophylaxis and on demand. On demand segment was valued at more than USD 3,061 million in 2021 and is projected to grow at 5.2% CAGR through 2028. This substantial segmental growth is attributable to better clinical outcomes delivered by on demand treatment in hemophilia patients. This treatment allows stopping hemorrhages quickly, lessening joint pain, and restoring joint mobility among others. This on demand therapy is widely used to treat patients with mild or moderate hemophilia that tend to bleed less often with clotting factor. This treatment therapy enables patients to keep a few doses of factor at home in case of a bleed. Adult patients switch to on-demand treatment for numerous reasons including inconvenience of visiting doctors, high cost associated with continuous prophylactic therapy, etc. Thus, pertaining to several advantages, this treatment demand would accelerate the industry landscape in analysis timeframe.
 

Rising awareness related to factor replacement therapy would enhance the segmental outlook

Based on therapy, the hemophilia treatment market is segmented as factor replacement therapy and non-factor replacement therapy. The factor replacement therapy segment was valued at over USD 9,411 million in 2021. This segment share is owing to numerous advantages in treating bleeding episodes or preventing bleeding. The factor replacement therapy allows the precise treatment through injecting a clotting factor concentrate into a vein that help blood to clot normally. This therapy also aids in preventing severe blood loss and problems from bleeding such as injury to muscle, joints, and organs. The recent advancements allow these therapies to be performed at home and can be easily stored, thereby increasing the demand for these treatments positively. Thus, the demand for factor replacement therapy owing to its associated advantages will amplify the hemophilia treatment market outlook in the estimation timeframe.
 

Advent of novel drugs in hemophilia treatment procedures are expected to boost the market size

Based on drug class, the hemophilia treatment market is segmented as vasopressin and coagulation factors. The coagulation factors segment was valued at over USD 10,486 million in 2021 and will progress at significant growth rate during the forecast timeframe. The FVIII concentrates are the coagulation factors that replace deficient FVIII in patients with hemophilia A. Similarly, Factor IX is used in the treatment of hemophilia B. These drugs help to achieve a normal hematologic response to hemorrhage or preventing hemorrhage. The most common issue of treatment for severe hemophilia is the development of inhibitors. Thus, in around 80% of patients, immune tolerance therapy involving high-dose coagulation factor infusions directed over a long period to eliminate inhibitors. These drugs are commonly given intravenously to stop or prevent bleeding, treating bleeding joints, etc. Additionally, the increasing investment in R&D activities related to innovations in coagulation factors is expected to significantly drive the market forecasts.
 

Several advantages delivered by the nasal route of drug administration are expected to fuel the industry growth

Based on route of administration, the hemophilia treatment market is segmented as injectable and nasal spray. The nasal spray segment is projected to grow at 5.8% CAGR to reach over USD 1,373 million by 2028. This considerable segment growth is attributable to suitability over invasive methods, higher efficiency, minimal toxicities, and improved outcomes among others. The nasal route of drug administration delivers numerous benefits comprising a rapid & high systemic availability, the possibility of targeting medications directly from the nasal cavity to the brain, etc. These nasal sprays are recommended for patients with mild hemophilia in those medicines comprising desmopressin acetate used for bleeding in the mucous membranes of the nose and mouth, etc. Hence, several advantages delivered by the nasal route of drug administration are expected to upsurge the adoption rate of hemophilia medication.
 

Availability of advanced hemophilia treatment and skilled professionals in hemophilia treatment centers is amplifying the business expansion

Based on end-use, the market is segmented as hospitals, clinics, hemophilia treatment centers, and others. The hemophilia treatment centers segment is anticipated to progress at 4.6% CAGR to reach around USD 6,108 million by 2028. This significant segmental growth is owing to rising awareness regarding hemophilia treatment centers, easy access to advanced medical treatment, emphasis on offering comprehensive care, and significant upsurge in the number of hemophilia treatment centers across the globe, etc. As per the National Hemophilia Foundation (NHF), around 141 federally funded hemophilia treatment centers are operating across the U.S. These centers are intended to deliver comprehensive care for patients with bleeding disorders comprising hemophilia. These centers are also involved in providing emotional support along with assisting in bleeding disorder issues, thereby increasing the preference for these healthcare facilities.
 

Growing demand for advanced hemophilia treatment in the UK is anticipated to fuel the business outlook

UK hemophilia treatment market exceeded USD 266 million in 2021. This higher share is attributable to a growing prevalence of hemophilia, surging awareness related to early diagnosis, and favourable initiatives among others. The UK hemophilia society is actively operating to spread awareness related to the effective prevention and treatment of hemophilia to reduce the risk of complications. The increasing disease prevalence along with favourable initiatives are expected to stimulate the business revenue in the country. Additionally, numerous variables comprising rising inclination towards prophylaxis treatment, growing healthcare expenditure, and demand for improvised medical facilities are promoting business revenue in the UK. Thus, the above-mentioned factors are projected to help sustain the business growth in the country.
 

Companies are emphasizing on product development and market expansion strategies to maximum market share

Some of the major players operating in the hemophilia treatment industry are Bayer Healthcare, Biogen, Biotest AG, CSL Behring, Ferring B.V., Genentech, Kedrion, Novo Nordisk, and Octapharma among others. These players are emphasizing on new product developments and launches in order to expand their product offerings in the market. For instance, in October 2018, Genentech received the U.S. FDA approval for its Hemlibra medication. This medicine can be administered subcutaneously for hemophilia A to prevent or reduce the frequency of bleeding episodes in pediatric and adult patients. This product launch helped the company at capturing large customer base, further offering a competitive edge.